Radiation Exposure from Abdominal Imaging Studies in Patients with Intestinal Behçet Disease

Yoon Suk Jung*,†, Dong Il Park†, Chang Mo Moon†, Soo Jung Park*, Sung Pil Hong*, Tae Il Kim*, Won Ho Kim*, and Jae Hee Cheon*

*Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, and †Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Background/Aims: Recently, several studies have revealed that diagnostic imaging can result in exposure to harmful levels of ionizing radiation in inflammatory bowel disease patients. However, the extent of radiation exposure in intestinal Behçet disease (BD) patients has not been documented. The aim of this study was to estimate the radiation exposure from abdominal imaging studies in intestinal BD patients.

Methods: Patients with a diagnosis of intestinal BD established between January 1990 and March 2012 were investigated at a single tertiary academic medical center. The cumulative effective dose (CED) was calculated retrospectively from standard tables and by counting the number of abdominal imaging studies performed. High exposure was defined as CED >50 mSv.

Results: In total, 270 patients were included in the study. The mean CED was 41.3 mSv, and 28.1% of patients were exposed to high levels of radiation. Computed tomography (CT) accounted for 81.7% of the total effective dose. In multivariate analyses, predictors of high radiation exposure were azathioprine/6-mercaptopurine use, surgery, and hospitalization.

Conclusions: Approximately a quarter of intestinal BD patients were exposed to harmful levels of diagnostic radiation, mainly from CT examination. Clinicians should reduce the number of unnecessary CT examinations and consider low-dose CT profiles or alternative modalities such as magnetic resonance enterography. (Gut Liver 2014;8:380-387)

Key Words: Intestinal Behcet disease; Clinical course; Prognostic factors; Radiation

INTRODUCTION

The risks of protracted exposure to low-level ionizing radiation, including diagnostic radiation, have been acknowledged for decades, although the carcinogenic potential resulting from diagnostic radiation exposure has been debatable.1 A study involving 15 developed countries reported that between 0.6% and 1.8% of all malignancies resulted from diagnostic medical radiation.2 Irradiation with as little as 50 milli-Sieverts (mSv) from imaging-related radiation exposure has been implicated in the development of certain solid tumors, particularly of the large bowel and bladder.3

Inflammatory bowel disease (IBD) itself increases the risk of colorectal and small intestinal cancers4-6 and medications such as azathioprine, 6-mercaptopurine (6-MP), and infliximab are associated with an increased risk of lymphoma.7,8 This is of clinical concern for IBD patients, as IBD often presents at a young age and patients are thus repeatedly exposed to diagnostic medical radiation over the course of their disease, further increasing the risk of malignancy. Several recent studies examined radiation exposure from diagnostic medical imaging in IBD patients and reported that 5% to 24% of IBD patients have received potentially harmful levels of radiation, defined as ≥50 mSv.9-14

Intestinal Behçet disease (BD) is diagnosed by the presence of typical intestinal ulcers and systemic symptoms meeting the BD diagnostic criteria.15 Similarly to IBD, including Crohn’s disease (CD) and ulcerative colitis, intestinal BD is a chronic IBD having a fluctuating course characterized by repeated episodes of relapse and remission.16 The chronic relapsing nature of intestinal BD often requires repeat diagnostic imaging. In addition, diagnostic imaging is essential for patients with in-
Intestinal BD for perioperative evaluation because intestinal BD often requires surgical treatment due to the high frequency of complications, such as intestinal perforations and fistulas.\(^{17-19}\) Radiation exposure from diagnostic imaging is expected to be become increasingly common for intestinal BD patients as it has for IBD patients, especially with increasing access to computed tomography (CT). However, the extent of diagnostic radiation exposure in patients with intestinal BD has never been specifically studied. Moreover, it would be valuable if patients at risk for a high level of radiation exposure could be identified, as this might help in minimizing the risk in these patients. Accordingly, the objective of this study was to examine the cumulative effective ionizing radiation exposure from all abdominal imaging studies in a large number of patients with intestinal BD. In addition, we sought to identify factors associated with exposure to high levels of diagnostic radiation.

**MATERIALS AND METHODS**

1. **Study population and clinical evaluation**

All patients with an established diagnosis of intestinal BD who were registered in the intestinal BD database at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, between January 1990 and March 2012, were eligible for inclusion in the study. Patients who were at least 18 years old at diagnosis and who had been followed up for at least 6 months were included. Baseline clinical, endoscopic, and laboratory characteristics were extracted from a prospectively-collected database. Information regarding hospitalization, operation, and medical treatment modalities during the follow-up periods was obtained by reviewing medical records.

Intestinal BD was diagnosed according to established criteria based on colonoscopic features and clinical manifestations.\(^{35}\) Patients classified as definite, probable, and suspected were included in the study.

Some patients were first diagnosed with intestinal BD during surgery performed due to an acute or complicated presentation such as perforation. All other patients underwent colonoscopy at the time of diagnosis to identify the location and shape of the intestinal ulcer. Lesions with less than five ulcers that were oval in shape, deep, had discrete borders, and were located in the ileocecal area were defined as typical ulcerations.\(^{20}\) Ulcers that did not fulfill all of these criteria were defined as atypical. Surgery was defined as an intestinal resection related to intestinal BD. The definition of hospitalization included only intestinal BD-related admissions.

Intestinal BD activity was measured using the disease activity index for intestinal Behçet disease (DAIBD), as described.\(^{21}\) The DAIBD ranges in value from 0 to 325, with higher scores reflecting greater disease activity.

### Table 1. Radiation Dose from Common Abdominal Imaging Studies

| Imaging study                | Effective dose of radiation, mSv |
|-----------------------------|----------------------------------|
| Plain abdominal X-ray       | 0.7                              |
| CT abdomen                  | 10                               |
| CT pelvis                   | 10                               |
| Small bowel follow-through  | 3                                |
| Barium enema                | 7.2                              |

CT, computed tomography.

2. **Determination of radiation exposure**

Almost all imaging resulting in exposure to diagnostic medical radiation consisted of plain abdominal X-rays (AXR), CT scans of the abdomen and/or pelvis, CT enterography (CTE), small bowel follow-through (SBFT), and barium enema. The total effective dose of radiation received from AXR, SBFT, and barium enema was each calculated according to published standardized tables (Table 1).\(^{22}\) The effective dose for CT of the abdomen and/or pelvis and CTE were calculated by multiplying the dose-length product (DLP) by a factor of 0.015, which is the dose conversion factor for the abdomen and pelvis according to the guidelines provided in Publication 103 of the International Commission on Radiological Protection.\(^{23}\) When the DLP of CT of the abdomen and/or pelvis was not recorded in CT scan reports it was estimated based upon published standardized tables (Table 1). Cumulative effective dose (CED) was calculated for each patient by summing the effective doses of radiation from the time of diagnosis of intestinal BD until the time of data review. High cumulative exposure to diagnostic radiation was defined as CED exceeding 50 mSv.

This study was approved by the Institutional Review Board of Severance Hospital, Seoul, Korea.

3. **Statistical analysis**

The software program SPSS version 12 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. The chi-square or Fisher exact test was used to compare categorical variables. Student t-test or the Mann-Whitney U test was used to compare numerical variables between groups. p-values <0.05 were considered statistically significant. We constructed multivariate logistic regression models to identify independent factors associated with high CED (≥50 mSv). Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.

**RESULTS**

1. **Patient demographics**

A total of 270 patients with intestinal BD were included. Their mean age at diagnosis of BD, the onset of intestinal symptoms, and the diagnosis of intestinal BD were 38.7, 40.6, and 41.4 years, respectively. Of 270 patients, 123 (45.6%) were men.
and the mean follow-up duration after diagnosis was 7.5 years (range, 0.5 to 22.3 years). The most common intestinal symptom and location were abdominal pain (217 patients, 80.4%) and ileocecal area (255 patients, 94.4%), respectively. Twenty-eight patients who were first diagnosed at the time of operation as having intestinal BD were excluded from the analysis of colonoscopy characteristics.

2. Diagnostic radiation exposure

The total number of abdominal imaging examinations among all patients was 3,114, of which 2,623 (84.2%), 433 (13.9%), 50 (1.6%), and eight (0.3%) were AXR, CT (of these, 40 [1.3%] were CTE), SBFT, and barium enema, respectively. CT imaging accounted for 81.7% (9,103/11,146 mSv) of total effective dose from abdominal imaging studies (Fig. 1). The mean and median CED per patients from abdominal imaging were 41.3 and 15.8 mSv, respectively. The annual mean and median effective dose were 11.1 and 1.4 mSv/yr, respectively. One hundred and sixty-eight patients (62.2% of cohort) underwent at least one abdominal imaging study. Seventy-six of the 270 patients (28.1%) received CED exceeding 50 mSv (Fig. 2).

3. Factors associated with high cumulative exposure to diagnostic radiation

Table 2 shows the differences between patients with a CED greater and less than 50 mSv. The mean age at diagnosis of intestinal BD, age at onset of intestinal symptoms, and age at diagnosis of BD were all significantly lower in patients with a CED ≥50 mSv than those with a CED <50 mSv. White blood cell count, erythrocyte sedimentation rate, C-reactive protein level, and DAIBD at diagnosis were significantly higher in patients with a CED ≥50 mSv than those with a CED <50 mSv, whereas albumin levels were significantly lower in patients with a CED ≥50 mSv than those with a CED <50 mSv. Volcano-shaped ulcers were more common in patients with a CED ≥50 mSv, while oval and geographic-shaped ulcers were more common in patients with a CED <50 mSv. During the follow-up period, intestinal perforation and fistula occurred more frequently in patients with a CED ≥50 mSv than in those with a CED <50 mSv. In addition, patients with a CED ≥50 mSv required more frequent corticosteroid therapy, azathiopurine (AZA)/6-MP therapy, surgical treatment, and hospitalization than those with a CED <50 mSv.

No statistical differences in terms of sex, disease duration, family history of BD, symptoms and signs of systemic BD, type of intestinal ulcer, or diagnostic subtype were observed between patients with a CED greater and less than 50 mSv. In a multivariate logistic regression analysis that included significant variables from the univariate analysis, AZA/6-MP use (OR, 2.60; 95% CI, 1.10 to 6.16; p=0.030), surgery (OR, 3.35; 95% CI, 1.20 to 9.39; p=0.022), and hospitalization (OR, 4.11; 95% CI, 1.32 to 12.82; p=0.015) were independent explanatory factors associated with a high CED (Table 3).

DISCUSSION

Although several studies have reported significant diagnostic radiation exposure among patients with IBD, this study is the first to investigate the cumulative effective ionizing radiation exposure of patients with intestinal BD and to identify the subgroups of patients who are at greater risk of high cumulative exposure.

We found that a substantial proportion of intestinal BD patients were exposed to high doses of ionizing radiation from diagnostic tests. Over a mean follow-up period of 7.5 years, approximately a quarter of intestinal BD patients (28.1%) received cumulative doses in excess of 50 mSv, and the mean CED for intestinal BD was 41.3 mSv. Several recent studies investigat-
Table 2. Univariate Analysis of Factors Associated with Cumulative Effective Dose ≥50 mSv

| Factor                                             | CED <50 mSv (n=194) | CED ≥50 mSv (n=76) | p-value |
|----------------------------------------------------|---------------------|--------------------|---------|
| Age at diagnosis of intestinal BD, yr              | 42.5±12.1           | 38.6±11.1          | 0.015   |
| Age at onset of intestinal symptoms, yr            | 41.7±12.4           | 37.9±11.3          | 0.014   |
| Age at diagnosis of BD, yr                         | 39.8±12.5           | 35.9±11.0          | 0.018   |
| Male sex                                           | 91 (46.9)           | 32 (42.1)          | 0.476   |
| Disease duration, yr                               | 7.4±5.1             | 7.8±4.6            | 0.511   |
| Family history of BD                               | 8 (4.1)             | 1 (1.3)            | 0.452   |
| Symptoms and signs of BD                           |                     |                    |         |
| Oral ulcer                                         | 175 (90.2)          | 74 (97.4)          | 0.073   |
| Genital ulcer                                      | 76 (39.2)           | 39 (51.3)          | 0.070   |
| Ocular lesion                                      | 35 (18.0)           | 16 (21.1)          | 0.570   |
| Skin lesions                                       | 81 (41.8)           | 36 (47.4)          | 0.402   |
| Arthritis/arthralgia                               | 60 (30.9)           | 25 (32.9)          | 0.754   |
| Laboratory findings at diagnosis                   |                     |                    |         |
| WBC, 10⁶/L                                         | 7,979±3,500         | 9,977±5,316        | 0.003   |
| Hemoglobin, g/dL                                   | 12.1±2.0            | 11.9±2.4           | 0.578   |
| ESR, mm/hr                                         | 32.5±25.9           | 42.7±31.3          | 0.013   |
| CRP, mg/dL                                         | 1.7±2.4             | 4.4±4.9            | <0.001  |
| Albumin, g/dL                                      | 4.2±0.6             | 3.9±0.7            | 0.002   |
| DAIBD* at diagnosis                                | 61±40               | 95±47              | <0.001  |
| Shape of intestinal ulcer*                         |                     |                    |         |
| Oval/geographic                                    | 129 (73.7)          | 35 (52.2)          | 0.001   |
| Volcano                                            | 46 (26.3)           | 32 (47.8)          |         |
| Types of intestinal ulcer*                         |                     |                    |         |
| Typical type                                       | 104 (59.4)          | 40 (59.7)          | 0.969   |
| Atypical type                                      | 71 (40.6)           | 27 (40.3)          |         |
| Diagnostic subtypes of intestinal BD*             |                     |                    |         |
| Definite                                           | 79 (45.1)           | 34 (50.7)          | 0.137   |
| Probable                                           | 73 (41.7)           | 30 (44.8)          |         |
| Suspected                                          | 23 (13.1)           | 3 (4.5)            |         |
| Intestinal complication                            |                     |                    |         |
| Perforation                                        | 14 (7.2)            | 19 (25.0)          | <0.001  |
| Fistula†                                           | 7 (3.6)             | 13 (17.1)          | <0.001  |
| Stricture                                          | 12 (6.2)            | 6 (7.9)            | 0.613   |
| Abscess                                            | 5 (2.6)             | 3 (3.9)            | 0.691   |
| Medication                                         |                     |                    |         |
| 5-ASA/sulfasalazine                                | 179 (92.3)          | 72 (94.7)          | 0.476   |
| Corticosteroids                                    | 70 (36.1)           | 65 (85.5)          | <0.001  |
| Azathiopurine/6-MP                                 | 38 (19.6)           | 48 (63.2)          | <0.001  |
| Surgery†                                           | 40 (20.6)           | 45 (59.2)          | <0.001  |
| Hospitalization†                                   | 89 (45.9)           | 70 (92.1)          | <0.001  |

Data are presented as mean±SD or number (%).
CED, cumulative effective dose; BD, Behçet disease; WBC, white blood cell count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAIBD, disease activity index for intestinal Behçet disease; 5-ASA, 5-aminosalicylic acid; 6-MP, 6-mercaptopurine.
*Twenty-eight patients who were first diagnosed with intestinal BD at the time of operation were excluded from the analysis of colonoscopic characteristics; †Excluded anal fistula formation; ‡Intestinal resection related to intestinal BD; §Intestinal BD-related admission.
Due to the high frequency of acute complications such as intestinal perforations, intestinal BD often requires surgical treatment. AZA and 6-MP have been associated with an increased risk of lymphoma in IBD patients. The reason surgery was associated with increased surgical risk in CD patients has never been examined, AZA/6-MP use and radiation exposure by diagnostic imaging could synergistically increase the development of malignancies. Intestinal BD often requires surgical treatment even after surgical treatment, and occasionally requires repeated surgeries. Intestinal BD also recurs frequently, and hospitalization underwent more diagnostic imaging modalities to guide further management. AZA and 6-MP have been associated with an increased risk of lymphoma in IBD patients. Although lymphoma risk in intestinal BD patients treated with these medications has never been examined, AZA/6-MP use and radiation exposure by diagnostic imaging could synergistically increase the development of malignancies. Intestinal BD often requires surgical treatment because of the high frequency of acute complications such as intestinal perforations. Intestinal BD also recurs frequently, even after surgical treatment, and occasionally requires repeated surgeries. The reason surgery was associated with increased radiation exposure could be because of repeated assessments.

### Table 3. Multivariate Analysis for Factors Associated with Cumulative Effective Dose ≥50 mSv

| Factor                                      | OR  | 95% CI   | p-value |
|---------------------------------------------|-----|----------|---------|
| Age at diagnosis of intestinal BD, yr*     | 0.95| 0.81-1.11| 0.495   |
| Age at onset of intestinal symptoms, yr*   | 1.00| 0.88-1.14| 0.987   |
| Age at diagnosis of BD, yr*                | 1.04| 0.95-1.14| 0.404   |
| Laboratory findings at diagnosis           |     |          |         |
| WBC, 10^9/L                                | 1.00| 1.00-1.00| 0.141   |
| ESR, mm/hr                                 | 1.00| 0.99-1.02| 0.765   |
| CRP, mg/dL                                 | 1.10| 0.96-1.27| 0.158   |
| Albumin, g/dL                              | 1.52| 0.71-3.22| 0.280   |
| DAIBD* at diagnosis                        | 0.99| 0.98-1.01| 0.499   |
| Shape of intestinal ulcer                  | 0.70| 0.30-1.63| 0.405   |
| Perforation                                 | 2.90| 0.65-12.92| 0.162  |
| Fistula                                    | 1.27| 0.31-5.27| 0.738   |
| Corticosteroids                            | 2.83| 0.96-8.32| 0.059   |
| Azathiopurine/6-MP                         | 2.60| 1.10-6.16| 0.030   |
| Surgery                                    | 3.35| 1.20-9.39| 0.022   |
| Hospitalization†                           | 4.11| 1.32-12.82| 0.015  |

OR, odds ratio; CI, confidence interval; BD, Behçet disease; WBC, white blood cell count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAIBD, disease activity index for intestinal Behçet disease; 6-MP, 6-mercaptopurine.

*Mean±SD; †Excluded anal fistula formation; ‡Intestinal resection related to intestinal BD; §Intestinal BD-related admissions.
before deciding on surgery and the need to monitor postoperative complications. Recent studies in Western countries showed similar results concerning risk factors for increased radiation exposure in IBD patients. Palmer et al. showed that hospitalization and surgery were associated with high cumulative exposure in IBD. Several other studies and a meta-analysis of six studies also revealed that surgery is a predictor of excessive radiation exposure in IBD patients. To date, about 10 studies examined the diagnostic radiation exposure of IBD patients. However, only one of these studies investigated the incidence of cancer. Desmond et al. study which included 354 CD patients reported that during the follow-up period (mean, 6.7 years), malignancies occurred in seven patients, five of whom developed skin cancers and two of whom were diagnosed with gastrointestinal (GI) malignancy. In all but one case, CED was less than 75 mSv when the cancer was diagnosed. Therefore, a causal link with diagnostic radiation exposure is not clear. Of 270 intestinal BD patients who included in this study, no one developed malignancy. Although there is no evidence that intestinal BD is associated with GI malignancies to date and there is no data available regarding radiation risk for cancer in intestinal BD or IBD, several studies provide information regarding risk of radiation-induced cancer. It is estimated that up to 2% of malignancies could be attributed to diagnostic medical radiation and there are 5,500 deaths due to radiation-induced cancer in the United States each year. In addition, the U.S. National Research Council estimates that one patient will develop a radiation-induced cancer in their lifetime out of every 1,000 patients undergoing a 10 mSv CT abdominal scan. Although these estimations were from general population, we expect the similar results from patients with intestinal BD or IBD. Considering the low overall incidence of cancers in patients with IBD and the low incidence of intestinal BD, large cohort study with follow-up extended to several decades is needed to acquire information regarding radiation risk for cancer in IBD or intestinal BD.

Our study had several limitations. First, this study did not include non-GI imaging in calculating exposure, which could result in underestimation of the total effective dose of radiation received. However, most non-GI imaging would have been plain radiographs, and radiation exposure from these investigations is negligible compared to CT. The effective dose from a chest X-ray (CXR), for example, is around 0.02 mSv, and the effective dose from CT scan of the abdomen and pelvis is equivalent to the effective dose of approximately 1,000 CXRs. Second, this was a retrospective study with a potentially biased design. However, the retrospective nature of the study could be construed as an advantage. The retrospective approach could avoid any confounding influence on investigator behavior that may occur with a prospective study and more accurately reflect clinical practice. Third, the estimated radiation dose, based on published standardized tables, may have been greater or less than the actual exposure. However, we captured the DLP for approximately two-thirds of the CT scans performed and the calculated mean values (20.6 mSv) were similar to standard estimates of CT scans of the abdomen and pelvis (20 mSv). Finally, this was a hospital-based study and thus referral-center bias with inclusion of more severe cases in our cohort cannot be excluded, although patients with intestinal BD are generally managed by gastroenterology specialists in Korea.

In conclusion, the exposure to diagnostic radiation in patients with intestinal BD was high, mainly due to CT examination. One in four patients with intestinal BD was exposed to harmful amounts of diagnostic radiation. Patients who required immunosuppressants such as AZA/6-MP, surgery, or hospitalization were at greater risk of high radiation exposure. Given that intestinal BD is a life-long illness, clinicians caring for patients with intestinal BD need to consider cumulative radiation exposure, particularly from repeated CT scanning, and should perform these examinations only when the results can affect the patient’s management. In addition, the availability of low-dose CT profiles and alternative imaging modalities such as MR imaging needs to be increased.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This study was supported by a grant from the Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A111428).

REFERENCES

1. Wall BF, Kendall GM, Edwards AA, Bouffler S, Muirhead CR, Meara JR. What are the risks from medical X-rays and other low dose radiation? Br J Radiol 2006;79:285–294.
2. Berrington de González A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004;363:345–351.
3. Brenner DJ, Doll R, Goodhead DT, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A 2003;100:13761–13766.
4. Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TL. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724–2729.
5. Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am 2006;35:517–531.
6. Persson PG, Karlén P, Bernell O, et al. Crohn’s disease and
cancer: a population-based cohort study. Gastroenterology 1994;107:1675–1679.
7. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121–1125.
8. Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between inflammmatibulax and lymphoma in Crohn’s disease. Gastroenterology 1999;117:1433–1437.
9. Newnham E, Hawkes E, Surender A, James SL, Geary R, Gibson PR. Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy? Aliment Pharmacol Ther 2007;26:1019–1024.
10. Desmond AN, O’Regan K, Curran C, et al. Crohn’s disease: factors associated with exposure to high levels of diagnostic radiation. Gut 2008;57:1524-1529.
11. Levi Z, Fraser E, Krongrad R, et al. Factors associated with radiation exposure in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009;30:1128–1136.
12. Kroecker KL, Lam S, Birchall I, Fedorak RN. Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study. J Clin Gastroenterol 2011;45:34–39.
13. Fuchs Y, Markowitz J, Weinstein T, Kohn N, Choi-Rosen J, Levine J. Pediatric inflammatory bowel disease and imaging-related radiation: are we increasing the likelihood of malignancy? J Pediatr Gastroenterol Nutr 2011;52:280–285.
14. Sauer CG, Kugathasan S, Martin DR, Applegate KE. Medical radiation exposure in children with inflammatory bowel disease estimates high cumulative doses. Inflamm Bowel Dis 2011;17:2326-2332.
15. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet’s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol 2009;104:2492–2499.
16. Ebert EC. Gastrointestinal manifestations of Behcet’s disease. Dig Dis Sci 2009;54:201–207.
17. Sayek I, Aran O, Uzunalmoglu B, Hersek E. Intestinal Behcet’s disease: surgical experience in seven cases. Hepatogastroenterology 1991;38:81–83.
18. Ketch LL, Buerk CA, Liechty D. Surgical implications of Behcet’s disease. Arch Surg 1980;115:759–760.
19. Moon CM, Cheon JH, Shin JK, et al. Prediction of free bowel perforation in patients with intestinal Behcet’s disease using clinical and colonoscopic findings. Dig Dis Sci 2010;55:2904–2911.
20. Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behcet’s disease. Inflamm Bowel Dis 2001;7:243–249.
21. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet’s disease. Inflamm Bowel Dis 2011;17:605–613.
22. Hart D, Wall BF; Great Britain National Radiological Protection Board. Radiation exposure of the UK population from medical and dental X-ray examinations. Chilton: National Radiological Protection Board, 2002.
23. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37:1–332.
24. Peloquin JM, Pardi DS, Sandborn WJ, et al. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:2015–2022.
25. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Long-term clinical outcomes of Crohn’s disease and intestinal Behcet’s disease. Inflamm Bowel Dis 2013;19:99–105.
26. Jung YS, Park DI, Kim ER, et al. Quantifying exposure to diagnostic radiation and factors associated with exposure to high levels of radiation in Korean patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1852–1857.
27. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008;81:362–378.
28. Fletcher JG, Fidler JL, Bruining DH, Huprich JE. New concepts in intestinal imaging for inflammatory bowel diseases. Gastroenterology 2011;140:1795–1806.
29. Siddiki H, Fletcher JG, Hara AK, et al. Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn’s disease in the small bowel. Inflamm Bowel Dis 2011;17:778–786.
30. Allen BC, Baker ME, Einstein DM, et al. Effect of altering automatic exposure control settings and quality reference mAs on radiation dose, image quality, and diagnostic efficacy in MDCT enterography of active inflammatory Crohn’s disease. AJR Am J Roentgenol 2010;195:89–100.
31. Kamhadakone AR, Prakash P, Hahn PF, Sahani DV. Low-dose CT examinations in Crohn’s disease: Impact on image quality, diagnostic performance, and radiation dose. AJR Am J Roentgenol 2010;195:78–88.
32. Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008;247:64–79.
33. Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis 2011;17:1073–1080.
34. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet’s disease. Inflamm Bowel Dis 2011;17:1594–1602.
35. Palmer L, Herfarth H, Porter CQ, Fordham LA, Sandler RS, Kappelman MD. Diagnostic ionizing radiation exposure in a population-based sample of children with inflammatory bowel diseases. Am J Gastroenterol 2009;104:2816–2823.
36. Chatu S, Subramanian V, Pollok RC. Meta-analysis: diagnostic medical radiation exposure in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:529–539.
37. Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001;176:289–296.

38. National Research Council (US) Committee to Assess Health Risks from Exposure to Low Level of Ionizing Radiation. Health risks from exposure to low levels of ionizing radiation: BEIR VII, Phase 2. Washington, DC: National Academies Press, 2006.